Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma.
Saved in:
| Title: | Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma. |
|---|---|
| Authors: | Sidana S; Division of BMT and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, USA. Surbhi.sidana@stanford.edu., Bankova AK; Division of BMT and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, USA.; National Specialized Hospital for Hematological Diseases, Sofia, Bulgaria., Hosoya H; Division of BMT and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, USA., Kumar SK; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Holmes TH; Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford, USA., Tamaresis J; Department of Biostatistics, Stanford University School of Medicine, Stanford, USA., Le A; Division of BMT and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, USA.; Jasper Therapeutics, Stanford, USA., Muffly LS; Division of BMT and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, USA., Maysel-Auslender S; Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford, USA., Johnston L; Division of BMT and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, USA., Arai S; Division of BMT and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, USA., Lowsky R; Division of BMT and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, USA., Meyer E; Division of BMT and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, USA., Rezvani A; Division of BMT and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, USA., Weng WK; Division of BMT and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, USA., Frank MJ; Division of BMT and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, USA., Shiraz P; Division of BMT and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, USA., Maecker HT; Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford, USA., Lu Y; Department of Biostatistics, Stanford University School of Medicine, Stanford, USA., Miklos DB; Division of BMT and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, USA., Shizuru JA; Division of BMT and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, USA. |
| Source: | Blood cancer journal [Blood Cancer J] 2024 Oct 09; Vol. 14 (1), pp. 173. Date of Electronic Publication: 2024 Oct 09. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2044-5385 |
|---|---|
| DOI: | 10.1038/s41408-024-01152-1 |
